株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

腎臓病:パイプライン製品の分析

Kidney Disease - Pipeline Review, H1 2014

発行 Global Markets Direct 商品コード 264710
出版日 ページ情報 英文 106 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
腎臓病:パイプライン製品の分析 Kidney Disease - Pipeline Review, H1 2014
出版日: 2014年03月31日 ページ情報: 英文 106 Pages
概要

腎臓病は「沈黙の病気」と呼ばれています。腎臓病は、血液フィルターとして機能する腎臓内部のネフロン(腎単位)が損傷すると、発症します。これにより、体内の廃棄物や体液が蓄積するようになります。兆候や症状には、悪心、嘔吐、食欲不振、倦怠感や虚弱、睡眠障害、しゃっくり、足や足首の腫れなどがあります。素因として、年齢、糖尿病、高血圧、心臓病、喫煙、肥満、高コレステロールなどが挙げられます。

当レポートでは、腎臓病に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

腎臓病の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • Nektar Therapeutics
  • Chugai Pharmaceutical Co., Ltd.
  • LEO Pharma A/S
  • Teva Pharmaceutical Industries Limited
  • Zydus Cadila Healthcare Limited
  • Gentium S.p.A.
  • Celldex Therapeutics, Inc.
  • Osteologix Holdings Plc.
  • Ahn-Gook Pharmaceutical Co., Ltd.
  • DiaMedica Inc.
  • Upsher-Smith Laboratories, Inc.
  • TetraLogic Pharmaceuticals
  • ChemoCentryx, Inc.
  • Anexon, Inc.
  • 大塚ホールディングス
  • BIOPROJET SCR
  • Advicenne Pharma
  • ZS Pharma, Inc.
  • G1 Therapeutics, Inc.
  • AbbVie Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ADV-7809
  • benazepril hydrochloride
  • ADV-7103
  • tolvaptan
  • methylprednisolone
  • ZS-9
  • AGNPN-803
  • hydrocodone bitartrate ER
  • LEO-27847
  • DM-199
  • tiprolisant
  • ABT-614
  • ANX-042
  • CCX-872
  • RG-7641
  • CDX-1189
  • CU-NP
  • Necrostatin Program
  • Oligotide
  • NKTR-228
  • CCR2 Antagonist
  • CH-5451098
  • SkQR-1
  • TNT-009
  • SLR-080811 Derivative
  • AVE-0991
  • NBS-101
  • Prod-1
  • messenger RNA Therapeutics Program
  • AHRO-200
  • CDK-4/6 Inhibitors As Renal Protectants
  • A77-Based Monobody

パイプライン製品の最新動向

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC4695IDB

Global Markets Direct's, 'Kidney Disease - Pipeline Review, H1 2014', provides an overview of the Kidney Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Kidney Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Kidney Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Kidney Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Kidney Disease Overview
  • Therapeutics Development
    • Pipeline Products for Kidney Disease - Overview
    • Pipeline Products for Kidney Disease - Comparative Analysis
  • Kidney Disease - Therapeutics under Development by Companies
  • Kidney Disease - Therapeutics under Investigation by Universities/Institutes
  • Kidney Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Kidney Disease - Products under Development by Companies
  • Kidney Disease - Products under Investigation by Universities/Institutes
  • Kidney Disease - Companies Involved in Therapeutics Development
    • F. Hoffmann-La Roche Ltd.
    • Sanofi
    • Nektar Therapeutics
    • Chugai Pharmaceutical Co., Ltd.
    • LEO Pharma A/S
    • Teva Pharmaceutical Industries Limited
    • Zydus Cadila Healthcare Limited
    • Gentium S.p.A.
    • Celldex Therapeutics, Inc.
    • Osteologix Holdings Plc.
    • Ahn-Gook Pharmaceutical Co., Ltd.
    • DiaMedica Inc.
    • Upsher-Smith Laboratories, Inc.
    • TetraLogic Pharmaceuticals
    • ChemoCentryx, Inc.
    • Anexon, Inc.
    • Otsuka Holdings Co., Ltd.
    • BIOPROJET SCR
    • Advicenne Pharma
    • ZS Pharma, Inc.
    • G1 Therapeutics, Inc.
    • AbbVie Inc.
  • Kidney Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ADV-7809 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • benazepril hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADV-7103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tolvaptan - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methylprednisolone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZS-9 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AGNPN-803 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hydrocodone bitartrate ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LEO-27847 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DM-199 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tiprolisant - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ABT-614 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANX-042 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCX-872 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-7641 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CDX-1189 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CU-NP - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Necrostatin Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligotide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-228 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCR2 Antagonist - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5451098 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SkQR-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TNT-009 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SLR-080811 Derivative - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AVE-0991 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NBS-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Prod-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • messenger RNA Therapeutics Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AHRO-200 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CDK-4/6 Inhibitors As Renal Protectants - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • A77-Based Monobody - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Kidney Disease - Recent Pipeline Updates
  • Kidney Disease - Dormant Projects
  • Kidney Disease - Product Development Milestones
    • Featured News & Press Releases
      • Nov 07, 2013: La Jolla Pharmaceutical Company Presents Data at the Annual American Society of Nephrology Conference
      • May 02, 2013: Arena Pharma Withdraws European Marketing Authorization Application For Belviq
      • Mar 28, 2013: Cytori Therapeutics Receives US Patent Covering Method Of Treating Renal Diseases Using Adipose-derived Regenerative Cells
      • Jan 08, 2013: Medicure Announces Filing Of sNDA For Aggrastat Label Change
      • Nov 06, 2012: Lexicon Pharma Presents Phase IIb Results Of LX4211 At American Heart Association Annual Conference
      • Oct 17, 2012: Raptor Pharma Announces Presentation Of Procysbi Extension Study Data At American Society Of Nephrology Annual Meeting
      • Aug 03, 2012: New Published Data Demonstrate Endocyte's Targeted Small Molecule Drug Conjugate Approach Shows Promising Results In Polycystic Kidney Disease Model
      • Mar 05, 2012: Medistem To Begin Clinical Trials Using ERC Stem Cells For Renal, Lung And Peripheral Artery Disease
      • May 11, 2011: Rockwell Medical Receives US Patent For SFP Packaging And Method Of Use
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Kidney Disease, H1 2014
  • Number of Products under Development for Kidney Disease - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Development by Companies, H1 2014 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Kidney Disease - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014
  • Kidney Disease - Pipeline by Sanofi, H1 2014
  • Kidney Disease - Pipeline by Nektar Therapeutics, H1 2014
  • Kidney Disease - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014
  • Kidney Disease - Pipeline by LEO Pharma A/S, H1 2014
  • Kidney Disease - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014
  • Kidney Disease - Pipeline by Zydus Cadila Healthcare Limited, H1 2014
  • Kidney Disease - Pipeline by Gentium S.p.A., H1 2014
  • Kidney Disease - Pipeline by Celldex Therapeutics, Inc., H1 2014
  • Kidney Disease - Pipeline by Osteologix Holdings Plc., H1 2014
  • Kidney Disease - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2014
  • Kidney Disease - Pipeline by DiaMedica Inc., H1 2014
  • Kidney Disease - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014
  • Kidney Disease - Pipeline by TetraLogic Pharmaceuticals, H1 2014
  • Kidney Disease - Pipeline by ChemoCentryx, Inc., H1 2014
  • Kidney Disease - Pipeline by Anexon, Inc., H1 2014
  • Kidney Disease - Pipeline by Otsuka Holdings Co., Ltd., H1 2014
  • Kidney Disease - Pipeline by BIOPROJET SCR, H1 2014
  • Kidney Disease - Pipeline by Advicenne Pharma, H1 2014
  • Kidney Disease - Pipeline by ZS Pharma, Inc., H1 2014
  • Kidney Disease - Pipeline by G1 Therapeutics, Inc., H1 2014
  • Kidney Disease - Pipeline by AbbVie Inc., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Kidney Disease Therapeutics - Recent Pipeline Updates, H1 2014
  • Kidney Disease - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Kidney Disease, H1 2014
  • Number of Products under Development for Kidney Disease - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top